Marcus Groettrup

Prof. Marcus Groettrup

Division of Immunology, Department of Biology, Universität Konstanz, D-78457 Konstanz, Germany
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Cell
Verified
Journal Article
Closed access
EHEva M. Huber
Eva M. Huber
Michael BaslerMichael Basler
Michael Basler
RSRicarda Schwab
Ricarda Schwab
WHWolfgang Heinemeyer
Wolfgang Heinemeyer
CKChristopher J. Kirk
Christopher J. Kirk
MGMichael Groll
Michael Groll

11 December 2009 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
Marcus GroettrupMarcus Groettrup
Marcus Groettrup
CKChristopher J. Kirk
Christopher J. Kirk
Michael BaslerMichael Basler
Michael Basler

29 January 2013 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
HGHannah Gola
Hannah Gola
HEHarald Engler
Harald Engler
ASAnnette Sommershof
Annette Sommershof
HAHannah Adenauer
Hannah Adenauer
SKStephan Kolassa
Stephan Kolassa
IKIris Kolassa
Iris Kolassa
Posttraumatic stress disorder (PTSD) is associated with an enhanced risk for cardiovascular and other inflammatory diseases. Chronic low-level inflammation has been suggested as a potential mechanism linking these conditions. We investigated plasma cytokine levels as well as spontaneous and lipopolysaccharide (LPS)-stimulated cytokine production by peripheral blood mononuclear cells (PBMCs) in a group of 35 severely traumatized PTSD patients compared to 25 healthy controls. Spontaneous production of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α by isolated PBMCs was significantly higher in the PTSD compared to the control group and even correlated with PTSD symptom severity within the PTSD group. In contrast, circulating plasma levels of pro- and anti-inflammatory cytokines such as IL-6, IL-8, IL-10, TNF-α, or monocyte chemotactic protein (MCP)-1 were not significantly altered in PTSD patients compared to healthy controls. Our findings indicate that PBMCs of PTSD patients are already pre-activated in vivo, providing further evidence for low-grade inflammation in PTSD. This might possibly represent one psychobiological pathway from PTSD to poor physical health.

1 May 2005 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
MHMark Steffen Hipp
Mark Steffen Hipp
BKBirte Kalveram
Birte Kalveram
SRShahri Raasi
Shahri Raasi
Marcus GroettrupMarcus Groettrup
Marcus Groettrup
GSGunter Schmidtke
Gunter Schmidtke
FAT10 is a small ubiquitin-like modifier that is encoded in the major histocompatibility complex and is synergistically inducible by tumor necrosis factor alpha and gamma interferon. It is composed of two ubiquitin-like domains and possesses a free C-terminal diglycine motif that is required for the formation of FAT10 conjugates. Here we show that unconjugated FAT10 and a FAT10 conjugate were rapidly degraded by the proteasome at a similar rate. Fusion of FAT10 to the N terminus of very long-lived proteins enhanced their degradation rate as potently as fusion with ubiquitin did. FAT10-green fluorescent protein fusion proteins were not cleaved but entirely degraded, suggesting that FAT10-specific deconjugating enzymes were not present in the analyzed cell lines. Interestingly, the prevention of ubiquitylation of FAT10 by mutation of all lysines or by expression in ubiquitylation-deficient cells did not affect FAT10 degradation. Thus, conjugation with FAT10 is an alternative and ubiquitin-independent targeting mechanism for degradation by the proteasome, which, in contrast to polyubiquitylation, is cytokine inducible and irreversible.

7 January 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
Michael BaslerMichael Basler
Michael Basler
SMSarah Mundt
Sarah Mundt
TMTony Muchamuel
Tony Muchamuel
CMCarlo Moll
Carlo Moll
JJJing Jiang
Jing Jiang
CKChristopher J. Kirk
Christopher J. Kirk
Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system. The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes. Recently, we demonstrated a novel function of immunoproteasomes in cytokine production and T cell differentiation. In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS. ONX 0914 attenuated disease progression after active and passive induction of experimental autoimmune encephalomyelitis (EAE), both in MOG 35–55 and PLP 139–151 ‐induced EAE. Isolation of lymphocytes from the brain or spinal cord revealed a strong reduction of cytokine‐producing CD4 + cells in ONX 0914 treated mice. Additionally, ONX 0914 treatment prevented disease exacerbation in a relapsing‐remitting model. An analysis of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice. These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.

18 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJulia Koerner
Julia Koerner
DHDennis Horvath
Dennis Horvath
VHValerie L. Herrmann
Valerie L. Herrmann
AMAnna MacKerracher
Anna MacKerracher
BGBruno Gander
Bruno Gander
Marcus GroettrupMarcus Groettrup
Marcus Groettrup
With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic modality compared to conventional antitumor therapies. Cancer immunotherapy composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) particles containing antigens and toll-like receptor ligands induces vigorous antitumor immune responses in vivo. Here, we demonstrate the supreme adjuvant effect of the recently developed and pharmaceutically defined double-stranded (ds)RNA adjuvant Riboxxim especially when incorporated into PLGA particles. Encapsulation of Riboxxim together with antigens potently activates murine and human dendritic cells, and elevated tumor-specific CD8+ T cell responses are superior to those obtained using classical dsRNA analogues. This PLGA particle vaccine affords primary tumor growth retardation, prevention of metastases, and prolonged survival in preclinical tumor models. Its advantageous therapeutic potency was further enhanced by immune checkpoint blockade that resulted in reinvigoration of cytotoxic T lymphocyte responses and tumor ablation. Thus, combining immune checkpoint blockade with immunotherapy based on Riboxxim-bearing PLGA particles strongly increases its efficacy.